American Academy of Allergy, Asthma & Immunology

Currently, antibiotics comprise roughly 80% of prescribed pregnancy medications, and recent epidemiological studies have indicated a link between antibiotic use and dysbiosis.

Dr. Mathias noted that investigators are continuing to determine if age plays a role in peanut allergy risk and sensitization.

Itch intensity was highest at bedtime compared to all other time periods of the day.

This decision could further exacerbate health inequities among populations that are socioeconomically disadvantaged.

The study found that PARTICS, in addition to the usual care these patients received, reduced severe asthma exacerbations by 15.4% (p50.048) which corresponded to a reduction of 13 exacerbations/100 patient-years.

Patients with allergic asthma could often have no clinical history of atopic dermatitis.

Most cases had onset after 4 hours and were mild, which Dr. Anvari noted should not contraindicate future COVID-19 vaccine doses.

In data presented at AAAAI 2022, investigators examined anaphylaxis rates in Brooklyn between 2016-2019.

To date, dupilumab is the only biologic medicine to show positive, clinically meaningful phase 3 results in adults and adolescents with EoE.

Knowledge on distinguishing moderate and severe eczema increased the most after the video training.

Investigators from the Cincinnati Children’s Hospital Medical Center tested a new allergic reaction severity grading system.

Dr. McKeon speaks of how patients can be more involved with managing their asthma and allergies by avoiding exposures in their own homes.

The most common burden of disease were itching, dry or rough skin, and cracked skin.

Those who were breastfed for less than 4 months also had lower risks of developing atopic diseases.

Though telemedicine has improved upon school-based asthma programs across the country, Dr. Phipatanakul notes that the adoption of these programs can be difficult to implement.

Dr. Epstein provides updates on a joint study between members of AAAAI and the American College of Allergy on the relationship between epinephrine and post-immunotherapy injection waiting periods.

Urticaria and angioedema with oral mucocutaneous involvement were commonly labeled as anaphylaxis upon presentation.

Dr. Trivedi speaks of a new text-based program that helps provide asthma care to children from communities of color, as well as how COVID-19 affected school-based asthma programs.

The proportion of anaphylaxis episodes was higher in the cohort of patients with peanut allergies, compared to a control group of patients with non-peanut food allergies.

Dr. Zein speaks of the relationship between eosinophil count and COVID-19 illness and mortality, especially as it related to inhaled corticosteroid use.

Consideration of how immunotherapy may influence other allergic diseases, patient adherence options, and advancing assessment of peanut allergy options.

Younger patients are faring better, and for longer, with sublingual immunotherapy. A leading investigator discusses what more needs to be learned in the burgeoning field.

A pooled analysis of sleep disturbance-related outcomes showed the IgE inhibitor significantly benefits a burdensome symptom of CRSwNP.

From interpreting currently-understood risks to managing isolation-induced indoor allergen exposure, asthmatics may have concerns they address with clinicians.

A review of 3 new studies, which indicate the association between severe COVID-19 and the chronic disease is more intricate than previously thought.

From better education, to remote monitoring and consistent check-ins, clinicians may need to initiate better adherence in their younger, severely ill patients.

How dupilumab is observed to benefit EoE patients—and who may administer the biologic therapy.

An interview on the TSLP inhibitor's effect on exacerbations, hospitalizations, and disease progress over 52-week findings.

In data presented during AAAAI 21, researchers compared the 2006 and 2016 versions of the diagnostic criteria proposed by the NIAD/FAAN.

Perspective on how the interleukin-targeting biologic has unique benefit for the rare, under-resourced disease.